Dickinson Sally C, Vankemmelbeke Mireille N, Buttle David J, Rosenberg Krisztina, Heinegård Dick, Hollander Anthony P
Academic Rheumatology, University of Bristol, Avon Orthopaedic Centre, Southmead Hospital, BS10 5NB, Bristol, UK.
Matrix Biol. 2003 May;22(3):267-78. doi: 10.1016/s0945-053x(03)00034-9.
Cartilage oligomeric matrix protein (COMP) is a pentameric glycoprotein present in cartilage, tendon and ligament. Fragments of the molecule are present in the diseased cartilage, synovial fluid and serum of patients with knee injuries, osteoarthritis and rheumatoid arthritis. Although COMP is a substrate for several matrix metalloproteinases (MMPs), the enzymes responsible for COMP degradation in vivo have yet to be identified. In this study we utilised well-established bovine cartilage culture models to examine IL-1alpha-stimulated COMP proteolysis in the presence and absence of MMP inhibitors. COMP was released from bovine nasal cartilage, in response to IL-1alpha, at an intermediate time between proteoglycans and type II collagen, when soluble MMP levels in the culture medium were undetectable. The major fragment of COMP released following IL-1alpha-stimulation migrated with an apparent molecular mass of approximately 110 kDa (Fragment-110) and co-migrated with both the major fragment present in human arthritic synovial fluid samples and the product of COMP cleavage by purified MMP-9. However, the broad-spectrum MMP and ADAM inhibitor BB94 only partially inhibited the formation of Fragment-110 and failed to inhibit COMP release significantly. Therefore the results of these studies indicate a role for proteinases other than MMPs in the degradation of COMP in bovine cartilage. It was further demonstrated that purified COMP was cleaved by ADAMTS-4, but not ADAMTS-1 or -5, to yield a fragment which co-migrated with Fragment-110. Therefore this is the first demonstration of COMP as a substrate for ADAMTS-4, although it remains to be determined whether this enzyme plays a role in COMP degradation in vivo.
软骨寡聚基质蛋白(COMP)是一种存在于软骨、肌腱和韧带中的五聚体糖蛋白。该分子的片段存在于膝部损伤、骨关节炎和类风湿性关节炎患者的病变软骨、滑液和血清中。尽管COMP是几种基质金属蛋白酶(MMP)的底物,但体内负责COMP降解的酶尚未确定。在本研究中,我们利用成熟的牛软骨培养模型,在有和没有MMP抑制剂的情况下,检测白细胞介素-1α刺激的COMP蛋白水解情况。当培养基中可溶性MMP水平无法检测到时,COMP在蛋白聚糖和II型胶原之间的中间时间从牛鼻软骨中释放出来,这是对白细胞介素-1α的反应。白细胞介素-1α刺激后释放的COMP主要片段迁移时的表观分子量约为110 kDa(片段-110),与人关节炎滑液样本中存在的主要片段以及纯化的MMP-9切割COMP的产物共同迁移。然而,广谱MMP和ADAM抑制剂BB94仅部分抑制了片段-110的形成,并且未能显著抑制COMP的释放。因此,这些研究结果表明,除MMP外,蛋白酶在牛软骨中COMP的降解中也发挥作用。进一步证明,纯化的COMP被ADAMTS-4切割,但不被ADAMTS-1或-5切割,产生一个与片段-110共同迁移的片段。因此,这是首次证明COMP是ADAMTS-4的底物,尽管该酶是否在体内COMP降解中发挥作用仍有待确定。